Back to results
US 2004/0171816 A1Published application
Humanized antibodies that recognize beta amyloid peptide
OwnerDale B. Schenk, Guriq Basiinventors
Life of this patent
Estimating the term…
Abstract
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
Claims24
Humanized 10D5 antibody.
A humanized antibody, or fragment thereof, comprising a humanized light chain comprising three light chain complementarily determining regions (CDRs) from the mouse monoclonal antibody 10D5 and a light chain variable region framework sequence from a human immunoglobulin light chain;
- and a humanized heavy chain comprising three heavy chain CDRs from the mouse monoclonal antibody 10D5 and a heavy chain variable region framework sequence from a human immunoglobulin heavy chain;
- wherein the light chain CDRs have the following amino acid sequences:
- light chain CDR1:
- 26 Arg Ser Ser Gln Asn Ile Ile His Ser Asn Gly (residues 24-39 of SEQ ID NO:14) Asn Thr Tyr Leu Glu
- light chain CDR2:
- 27 Lys Val Ser Asn Arg Phe Ser (residues 55-61 of SEQ ID NO:14)
- light chain CDR3:
- 28 Phe Gln Gly Ser His Val Pro Leu Thr (residues 94-102 of SEQ ID NO:14)
- and the heavy chain CDRs have the following amino acid sequences:
- heavy chain CDR1:
- 29 Thr Ser Gly Met Gly Val Ser (residues 31-37 of SEQ ID NO:16)
- heavy chain CDR2:
- 30 His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser Leu Lys Ser (residues 52-67 of SEQ ID NO:
- 16) and,
- heavy chain CDR3:
- 31 Arg Pro Ile Thr Pro Val Leu Val Asp Ala Met Asp Tyr (residues 100-112 of SEQ ID NO:
- 16).
14 more elements
Dependencies are inferred from the claim text.